# A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

> **NCT01428453** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 124 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** 250mg rilapladib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01428453
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-01
- **Primary completion:** 2013-02-04
- **Final completion:** 2013-02-18
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428453, "A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01428453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*